Immunology company Nucleome Therapeutics announced on Monday the appointment of Dr Michelle Morrow as its chief scientific officer (CSO), effective 23 February 2026.
Dr Morrow has two decades of experience in drug discovery and development and executing R&D strategy across biotech and large pharma.
Most recently Dr Morrow was CSO at Avacta Therapeutics, providing strategic leadership of discovery and preclinical research and leading its oncology programme through candidate selection to IND approval. Earlier, she was SVP, head of invoX Therapeutics Innovation, following its acquisition of F-star Therapeutics.
Reacta Healthcare names new chair of board
Lario Therapeutics awarded USD2.4m in grants for neuronal calcium channel research
EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer
Merck reports positive Phase 3 data for Enflonsia in high-risk children across two RSV seasons
IBA and Shreeji sign agreement to deploy four cyclotrons for PET radiopharmaceuticals in India
AVEO Oncology completes first interim analysis in global Phase 3 FIERCE-HN study
Cedar Health Research opens new embedded research site within Texas Native Health
Merck and Mayo Clinic launch AI-driven drug discovery collaboration